Jessica Flores
Known title: Executive VP & CAOCIK: 0002003768
Associated companies
Transaction History
| SBRA | ▲ Buy | Grant | 382 | $0 | 8/31/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 385 | $0 | 5/29/2026 | View on chart |
| SBRA | ▼ Sell | Open Market | 15,231 | $302K | 3/25/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 368 | $0 | 2/27/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 3,198 | $0 | 2/10/2026 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 1,172 | $22K | 2/10/2026 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 3,128 | $61K | 1/8/2026 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 3,929 | $77K | 1/8/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 7,996 | $0 | 1/8/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 9,958 | $0 | 12/31/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 363 | $0 | 11/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 367 | $0 | 8/29/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 394 | $0 | 5/30/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 407 | $0 | 2/28/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 10,048 | $0 | 1/15/2025 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 4,085 | $69K | 1/15/2025 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 2,956 | $51K | 1/8/2025 | View on chart |
| SBRA | ▲ Buy | Grant | 8,813 | $0 | 12/27/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 321 | $0 | 11/29/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 348 | $0 | 8/30/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 397 | $0 | 5/31/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 5,976 | $0 | 3/1/2024 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 2,291 | $32K | 3/1/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 409 | $0 | 2/29/2024 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 1,382 | $18K | 1/31/2024 | View on chart |
| SBRA | ▲ Buy | Grant | 3,266 | $0 | 1/31/2024 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 1,359 | $19K | 1/5/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sabra Health Care REIT analysts lower price targets
UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.
Sabra Health Care REIT analysts lower price targets. UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.